๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Xiamen
Clinical trial register · China

Clinical Trials in Xiamen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital of Xiamen University64 Merck Sharp & Dohme LLC36 Bristol-Myers Squibb11 BeOne Medicines10 AbbVie8
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Xiamen

382 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Nudge-Based Shared Decision Making and Self-Management in Type 2 Diabetes: A Randomized Trial
NCT07129915Diabetes Mellitus, Type 2, Physician-Patient Relations, Self-management
Yunxuan Li
Not applicable
250
Xiamen
2025-11-01
Recruiting
To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome
NCT07208591Acute Respiratory Distress Syndrome (ARDS)
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Phase 3
406
Beijing, Xiamen, Guangzhou, Zunyi, Luoyang, Zhengzhou, Wuhan, Xiangtan
2025-10-31
Recruiting
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
NCT07296705Muscle Invasive Bladder Cancer (MIBC)
Fujian Medical University Union Hospital
Phase 2
25
Fuzhou, Putian, Quanzhou, Sanming, Xiamen, Zhangzhou, Nanchang, Jinan
2025-10-25
Active, closed
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
NCT07176390Arthritis, Rheumatoid
Merck Sharp & Dohme LLC
Phase 2
182
Beijing, Xiamen, Guangzhou, Xinxiang, Pingxiang, Linfen, รœrรผmqi, Linhai
2025-10-08
Not yet open
Analysis of Differences in Small Intestinal Microbiota Structure and Metabolites Between Patients With Irritable Bowel Syndrome and Healthy Individuals
NCT07212569Irritable Bowel Syndrome
Zhongshan Hospital Xiamen University
Observational
90
Xiamen
2025-10-01
Not yet open
A Study on Peginterferon Alfa-2b Combined With NAs in Compensated HBV Cirrhosis
NCT07183293HBV-related Liver Cirrhosis
Xiamen Humanity Hospital
Not applicable
30
Xiamen
2025-10
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762Urothelial Cancer
Bristol-Myers Squibb
Phase 2/3
470
Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Changsha, Nanjing, Nantong
2025-09-30
Recruiting
Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH)
NCT07198386NASH
Cascade Pharmaceuticals, Inc
Phase 2
120
Fuzhou, Xiamen, Suzhou, Shanghai, Hangzhou, Wenzhou
2025-09-30
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336Ulcerative Colitis
Genentech, Inc.
Phase 2
224
Fuzhou, Xiamen, Guangzhou, Huizhou, Zhengzhou, Wuhan, Changchun, Binzhou
2025-09-29
Active, closed
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytrudaยฎ in Multiple Resected Solid Tumors
NCT07160335Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
Shanghai Henlius Biotech
Phase 1
174
Hefei, Wuhu, Beijing, Hunan, Fuzhou, Xiamen, Lanzhou, Cangzhou
2025-09-26
Recruiting
Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
NCT07107256Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
246
Fuyang, Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-09-25
Recruiting
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged โ‰ฅ40 to โ‰ค85 Years With Chronic Obstructive Pulmonary Disease.
NCT07053423Chronic Obstructive Pulmonary Disease
Sanofi
Phase 4
218
Chengdu, Guangzhou, Hangzhou, Xiamen
2025-09-22
Not yet open
Multicenter Validation Study on Autism Screening Using a Machine-assisted System
NCT07006948Autism Spectrum Disorder, Early Developmental Impairment, Language Development Disorders
Children's Hospital of Fudan University
Observational
1,000
Hefei, Xiamen, Liuzhou, Harbin, Kunshan, Xi'an, Shanghai, Chengdu
2025-09-15
Recruiting
Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma
NCT07072351Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy, Immunotherapy, Chemotherapy
West China Hospital
Phase 1/2
88
Xiamen, Chengdu
2025-09-15
Not yet open
The Effect of Semaglutide on Bone Health
NCT07165158Osteoporosis, Osteoporosis Fracture, T2DM
The First Affiliated Hospital of Xiamen University
Phase 4
150
Xiamen
2025-09-15
Recruiting
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
NCT07043725HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
544
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Quanzhou, Xiamen, Zhangzhou
2025-09-15
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
Bristol-Myers Squibb
Phase 2/3
600
Hefei, Beijing, Fuzhou, Fyzhou, Xiamen, Lanzhou, Nanning, Harbin
2025-09-11
Recruiting
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771Carcinoma, Non-Small-Cell Lung
Bristol-Myers Squibb
Phase 2
182
Beijing, Xiamen, Nanning, Nanchang, Jinan, Linyi, Hangzhou, Linhai
2025-09-09
Recruiting
A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
NCT07137910Chronic Hepatitis B
Ausper Biopharma Co., Ltd.
Phase 2
200
Beijing, Jilin City, Chongqing, Xiamen, Guangzhou, Shenzhen, Nanning, Zhengzhou
2025-09-04
Not yet open
RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged โ‰ฅ50 Years in China
NCT07075029Acute Respiratory Infections (ARIs)
Huashan Hospital
Observational
28,800
Xiamen, Zhuhai, Zunyi, Xinxiang, Yichang, Nanjing, Jiujiang, Shenyang
2025-09-01
Recruiting
68Ga-XACP3 PET/CT in Prostate Cancer
NCT07242014Prostate Cancer, PET/CT, ACP3
The First Affiliated Hospital of Xiamen University
Not applicable
60
Xiamen
2025-09-01
Recruiting
We-INtervention Among Chinese HIV-serodiscordant Male Couples
NCT06639932HIV
City University of Hong Kong
Not applicable
320
Xiamen, Guangzhou, Shenzhen, Chengdu
2025-09-01
Not yet open
Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency
NCT07126288Growth Hormone Deficiency in Children, Growth Hormone Deficiency (GHD), Growth Hormone
Shenzhen Kexing Pharmaceutical Co., Ltd.
Phase 2/3
268
Xiamen, Nanyang, Xinxiang, Wuhan, Suzhou, Nanchang, Pingxiang, Changchun
2025-08-31
Recruiting
Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma
NCT07137052Nasopharyngeal Carcinoma (NPC), PET / CT
The First Affiliated Hospital of Xiamen University
Observational
732
Xiamen
2025-08-30
Recruiting
Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection
NCT07146100Chronic Hepatitis B
Ausper Biopharma Co., Ltd.
Observational
200
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou
2025-08-28
Recruiting
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07043400Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
BeOne Medicines
Phase 3
351
Hefei, Beijing, Xiamen, Anyang, Zhengzhou, Nanjing, Ganzhou, Shenyang
2025-08-27
Not yet open
Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen
NCT07137039Locally Advanced Hypopharyngeal Cancer
The First Affiliated Hospital of Xiamen University
Phase 2
34
Xiamen
2025-08-20
Active, closed
Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)
NCT07246889Chronic Hepatitis B
Ausper Biopharma Co., Ltd.
Phase 3
577
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou
2025-08-12
Recruiting
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors
NCT07105215Solid Tumors
RemeGen Co., Ltd.
Phase 1/2
312
Beijing, Fuzhou, Xiamen, Guilin, Nanning, Harbin, Luoyan, Luoyang
2025-08-11
Recruiting
Interventional Left Ventricular Assist System for PCI in CHIP Patients
NCT07053618High-Risk Percutaneous Coronary Intervention (High-risk PCI), Left Ventricular Assist Devices
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
286
Beijing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Changsha, Suzhou, Nanchang
2025-08-06
Not yet open
A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia
NCT07146386Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 3
728
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Zhangzhou, Dongguan, Shantou
2025-08
Recruiting
Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC
NCT07085234Locally Advanced Nasopharyngeal Carcinoma, Immunotherapy, Induction Therapy
The First Affiliated Hospital of Xiamen University
Phase 2
30
Xiamen
2025-07-30
Recruiting
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
NCT06780111Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 1/2
298
Hefei, Beijing, Xiamen, Zhengzhou, Xuzhou, Nanchang
2025-07-30
Recruiting
TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
NCT07044908RAS/BRAF Wild Type Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
72
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Meizhou, Shantou, Nanning
2025-07-30
Recruiting
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma
Merck Sharp & Dohme LLC
Phase 3
477
Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Xiamen, Guangzhou, Shenzhen
2025-07-16
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827Kidney Disease
Takeda
Phase 3
347
Beijing, Changping, Xiamen, Guangzhou, Shenzhen, Changsha, Baotou, Nanjing
2025-07-15
Recruiting
MITRIS China Post Market Clinical Follow-up (PMCF) Study
NCT07059793Mitral Valve Replacement
Edwards Lifesciences
Observational
250
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Xi'an, Jinan
2025-07-08
By invitation
Ultrasound Assessment of Fetal Growth Parameters
NCT07018362Fetal Clavicle Length, Fetal Scapular Width, Fetal Sternal Length, Fetal Scapular Length
The First Affiliated Hospital of Xiamen University
Observational
1,000
Xiamen
2025-07-01
Recruiting
Rectal NSAIDs With/Without PD Stent for PEP Prevention
NCT07117318Post-ERCP Acute Pancreatitis, Non-steroid Anti-inflammatory Drugs, Pancreatic Duct Stent Placement
Air Force Military Medical University, China
Not applicable
1,278
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Xi'an
2025-07-01
Not yet open
A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer
NCT07031154Non-Small Cell Lung Cancer, Adebrelimab, Apatinib
The First Affiliated Hospital of Xiamen University
Phase 2
43
Xiamen
2025-06-30
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
2,400
Hefei, Beijing, Xiamen, Guangzhou, Jiangmen, Liuzhou, Nanning, Xingtai
2025-06-30
Active, closed
Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation
NCT07034950Hepatic Neoplasm, Hepatic Cancer
The First Affiliated Hospital of Xiamen University
Phase 1/2
79
Xiamen
2025-06-29
Active, closed
Study on the Effective Dose and Safety of Esketamine in Hysteroscopic Surgery Under Monitored Anesthesia Care
NCT07034963Intrauterine Polyp, Intrauterine Synechiae
The First Affiliated Hospital of Xiamen University
Phase 1/2
95
Xiamen
2025-06-26
Recruiting
A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors.
NCT07185243Advanced Solid Tumors
Hangzhou Converd Co., Ltd.
Not applicable
24
Xiamen
2025-06-23
Recruiting
T-cell Developmental Status in Patients With Malignant Hematological Tumors
NCT07035938Hematologic Malignancy
The First Affiliated Hospital of Xiamen University
Observational
75
Xiamen
2025-06-22
Recruiting
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
NCT06933472Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Alebund Pharmaceuticals
Phase 3
264
Beijing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Nantong, Wuxi
2025-06-13
Recruiting
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
NCT06783647Advanced Solid Tumour
Nanjing Leads Biolabs Co.,Ltd
Phase 2
250
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Guilin, Nanning, Harbin
2025-06-11
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeOne Medicines
Phase 3
630
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Shijiazhuang, Harbin
2025-06-11
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568Endometrial Cancer
BioNTech SE
Phase 3
480
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shantou
2025-06-10
Recruiting
Indomethacin vs Diclofenac for Preventing PEP
NCT07071441ERCP, Pancreatitis, Non-steroidal Anti-inflammatory (NSAID), Indomethacin
Air Force Military Medical University, China
Not applicable
4,050
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Jilin City
2025-06-01
Active, closed
Mechanism and Application of Vitamin D in Idiopathic Sudden Sensorineural Hearing Loss
NCT07045883Idiopathic Sudden Sensorineural Hearing Loss
Zhongshan Hospital Xiamen University
Not applicable
197
Xiamen
2025-06-01
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
1,123
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2025-05-22
Recruiting
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT06962800Primary Membranous Nephropathy
Biogen
Phase 3
180
Fuyang, Beijing, Xichengqu Beijing, Xiamen, Lanzhou, Guangzhou, Shenzhen, Nanning
2025-05-22
Recruiting
A Study of ZL-1310 in Participants With Selected Solid Tumors
NCT06885281Solid Tumors
Zai Lab (Shanghai) Co., Ltd.
Phase 1/2
166
Beijing, Xiamen, Guangzhou, Harbin, Changsha, Changchun, Shanghai
2025-05-12
Recruiting
Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC
NCT06929936Non-Small Cell Lung Cancer, Myelosuppression
The First Affiliated Hospital of Xiamen University
Phase 2
33
Xiamen
2025-05-09
Recruiting
Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer Patients
NCT06956144Tumor, Carbonic Anhydrase IX
The First Affiliated Hospital of Xiamen University
Observational
113
Xiamen
2025-05-09
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
Biogen
Phase 3
454
Fuyang, Hefei, Beijing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-05-08
Recruiting
CHina Adrenal Venous saMPling InvestigatiON
NCT07252284Hyperaldosteronism, Adrenal Venous Sampling, Adrenalectomy
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
5,000
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou
2025-05-01
Recruiting
PET/CT for Trop2 ADC Response Evaluation NSCLC
NCT07151898NSCLC, Trop2, PET/CT
The First Affiliated Hospital of Xiamen University
Observational
50
Xiamen
2025-05-01
Recruiting
The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature
NCT06927310Idiopathic Short Stature
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
300
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Wuhan
2025-04-28
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
Mirati Therapeutics Inc.
Phase 3
630
Bengbu, Hefei, Beijing, Chongqing, Fuzhou Fujian, Xiamen, Guangzhou, Shantou
2025-04-24
Not yet open
Effects of Peginterferon Consolidation Therapy on Hepatic cccDNA Dynamics in CHB Patients Achieving Clinical Cure.
NCT06920329Chronic Hepatitis b
Xiamen Hospital of Traditional Chinese Medicine
Not applicable
30
Xiamen
2025-04-20
Recruiting
Dihydroartemisinin for the Treatment of Polycystic Ovary Syndrome
NCT06842524Polycystic Ovary Syndrome (PCOS)
Shanghai Zhongshan Hospital
Phase 2
150
Xiamen, Shanghai, Wenzhou
2025-04-16
Recruiting
Efficacy and Safety of Catheter abLation in patiEnts With seVere mitrAl regurgiTation and pErsistent Atrial Fibrillation: a Randomized Controlled Trial
NCT06883864Atrial Fibrillation (AF), Catheter Ablation, Atrial Functional Mitral Regurgitation
Beijing Anzhen Hospital
Not applicable
146
Hefei, Beijing, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2025-04-08
Recruiting
A Study of the Efficacy and Safety of Cyclosporin Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease
NCT06766357Moderate to Severe Dry Eye
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Phase 3
360
Xiamen
2025-04-03
Recruiting
Structural Heart Surgery Assist System for Transcatheter Mitral Valve Edge-to-Edge Repair (TEER).
NCT07055919Mitral R, Mitral Regurgitation
Xiamen Cardiovascular Hospital, Xiamen University
Not applicable
112
Xiamen
2025-03-22
Recruiting
TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
NCT06829784Asthma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
660
Bozhou, Hefei, Lu'an, Tongling, Beijing, Xiamen, Zhangzhou, Lanzhou
2025-03-21
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,000
Bengbu, Chongqing, Xiamen, Guangzhou, Nanning, Zhengzhou, Wuhan, Xiangyang
2025-03-16
Recruiting
Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML
NCT06737523Acute Myeloid Leukemia, Relapse, Refractory AML
The First Affiliated Hospital of Xiamen University
Phase 1
30
Xiamen
2025-03-15
Active, closed
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485Metastatic Castration-resistant Prostate Cancer
Celgene
Phase 3
960
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Huizhou, Changzhou, Nanjing
2025-03-13
Recruiting
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
NCT06854445Diffuse Large Cell B-lymphoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
55
Wuhu, Xiamen, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Zhengzhou
2025-03-12
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496Psoriatic Arthritis
Takeda
Phase 3
600
Bengbu, Beijing, Xiamen, Guangzhou, Shenzhen, Luoyang, Wuhan, Zhuzhou
2025-03-10
Recruiting
Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer
NCT06521866Advanced Colorectal Carcinoma, Immunotherapy
Fudan University
Phase 2
208
Fuzhou, Xiamen, Lanzhou, Zhengzhou, Huaian, Jinan, Taian, Shanghai
2025-03-01
Recruiting
To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension
NCT07051811Essential Hypertension
Lepu Medical Technology (Beijing) Co., Ltd.
Not applicable
213
Beijing, Chongqing, Xiamen, Lanzhou, Shenzhen, Zhengzhou, Hohhot, Yinchuan
2025-02-25
Recruiting
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
NCT06811844Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy, Complete Response
The First Affiliated Hospital of Xiamen University
Phase 2
208
Xiamen, Zhangzhou, Haikou
2025-02-25
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276Extensive-Stage Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3
530
Beijing, Chongqing, Fuzhou, Xiamen, Shantou, Harbin, Wuhan, Changsha
2025-02-25
Recruiting
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
NCT06826118Lymphoma, Follicular Lymphoma, Refractory Lymphoma
The First Affiliated Hospital of Xiamen University
Phase 2
30
Xiamen
2025-02-08
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347Diffuse Large B-Cell Lymphoma
Merck Sharp & Dohme LLC
Phase 3
1,046
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Guiyang
2025-01-27
Not yet open
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
NCT06786312Small Cell Lung Cancer Extensive Stage
Fujian Cancer Hospital
Phase 2
34
Fuzhou, Xiamen
2025-01-25
Recruiting
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
NCT06589596Advanced Solid Tumor
BeOne Medicines
Phase 1
525
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou, Nanning
2025-01-10
Recruiting
Early Vitrectomy vs PRP in Early Proliferative Diabetic Retinopathy
NCT07586787Proliferative Diabetic Retinopathy (PDR)
Xiamen Ophthalmology Center Affiliated to Xiamen University
Not applicable
100
Beijing, Xiamen, Zhengzhou, Nanjing, Dalian
2025-01-01
Active, closed
A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection
NCT07183306Chronic Hepatitis B
Suzhou HepaThera Biotech Co., Ltd.
Phase 1/2
86
Beijing, Xiamen, Guangzhou, Qingyuan, Shanghai, Chengdu
2024-12-30
Recruiting
A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia
NCT07251309Hyperkalemia
Waterstone Pharmaceutical (Wuhan) Co., LTD.
Phase 3
420
Bengbu, Wuhu, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhanjiang, Huizhou
2024-12-23
Recruiting
Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients
NCT06651866Acute Myeloid Leukemia
The First Affiliated Hospital of Xiamen University
Phase 1
18
Xiamen
2024-12-12
Recruiting
68Ga-MY6349 PET/CT in Solid Tumors
NCT07046702Solid Tumor, Trop2, PET/CT
The First Affiliated Hospital of Xiamen University
Observational
300
Xiamen
2024-12-10
Recruiting
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
NCT06625593Advanced Solid Tumor
BeOne Medicines
Phase 1
168
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Nanning, Shijiazhuang, Harbin
2024-12-09
Recruiting
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
NCT06679140COVID-19 SARS-CoV-2 Infection
Pfizer
Phase 3
2,330
Chizhou, Beijing, Xiamen, Guangzhou, Nanning, Changsha, Nanchang, Changchun
2024-12-08
Active, closed
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis๏ผšBDLL Chinese Cohort
NCT06649721Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis
Huashan Hospital
Phase 3
120
Hefei, Beijing, Xiamen, Nanning, Liupanshui, Shijiazhuang, Harbin, Jiamusi
2024-11-27
Recruiting
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
NCT06564324Non Small Cell Lung Cancer
Nuvation Bio Inc.
Phase 3
194
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Zhengzhou
2024-11-27
Active, closed
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
NCT06698042Lung Cancer, Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
67
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Huizhou, Jiangmen, Liuzhou
2024-11-21
Recruiting
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
NCT06682169Graft-versus-host Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
182
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning
2024-11-20
Recruiting
ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
NCT06775860Atopic Dermatitis
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
552
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shaoguan
2024-11-14
Recruiting
A Clinical Follow-up Study on the Efficacy of Thumbtack Needle for Postoperative Sleep and Recovery Treatment
NCT06757023Postoperative Complications, Postoperative Pain, Acupuncture
The First Affiliated Hospital of Xiamen University
Observational
110
Xiamen
2024-11-13
By invitation
IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma
NCT06688175Nasopharyngeal Neoplasms, Elderly, Chemotherapy
The First Affiliated Hospital of Xiamen University
Phase 2
32
Xiamen
2024-11-13
Active, closed
A Real-world Study to Assess Safety of OZURDEXยฎ (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China
NCT06548568Diabetic Macular Edema
AbbVie
Observational
110
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Dalian, Xi'an, Qingdao
2024-11-13
Recruiting
Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT)
NCT06548971Acute Ischemic Stroke, Cerebral Infarction
Capital Medical University
Phase 3
1,184
Bengbu, Suzhou, Beijing, Haidian, Pinggu, Tongzhou, Fuzhou, Xiamen
2024-11-07
Recruiting
SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
NCT06676722Nasopharyngeal Cancinoma (NPC), SBRT, Immunotherapy
The First Affiliated Hospital of Xiamen University
Phase 2
20
Xiamen
2024-11-05
Recruiting
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
NCT06596694Gastrointestinal Cancer
Merck Sharp & Dohme LLC
Phase 1/2
180
Hefei, Fuzhou, Xiamen, Guangzhou, Nanning, Zhengzhou, Shanghai, Taiyuan
2024-11-03
Active, closed
Cola Ingestion for Esophageal Bolus Impaction
NCT06652620Esophageal Cancer
Fudan University
Not applicable
50
Xiamen, Yangzhou, Jingdezhen, Shanghai
2024-11-01
Recruiting
PET/CT for Trop2 ADC Response Evaluation Cancers
NCT07046689Breast Cancer, Trop2, PET/CT
The First Affiliated Hospital of Xiamen University
Observational
50
Xiamen
2024-11-01
Rows per page Showing 101–200 of 382
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/xiamen?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 382 of those studies with a site in Xiamen.

How many clinical trials are recruiting in Xiamen?

243 of the 382 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 45 have not yet opened recruitment, 91 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.